Purchase this article with an account.
M. J. Koss, A. Bauch, F. H. Koch; Micropulse versus Bevacizumab in Central Serous Retinopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):227.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
19 eyes of 19 patients (43.8 years, all male) with acute (n=7) and chronic (n=12) CSR were followed for 10 months after micro-pulsed 810nm focal diode lasercoagulation (group1; n=8), initial 1.5mg bevacizumab intravitreal injection (group2; n=5), or as a control group (group3; n=6). EDTRS visual acuity score, subthreshold static automated 10° perimetry, central macular thickness (CMT) with optical coherence tomography, and fluorescein angiography were performed at baseline, 6 weeks, 6 and 10 months post initial treatment.
VA increased significantly in group I and II (+6 and +5 letters, respectively, versus -4) with a change in spherical equivalent of -1.75dpt in group1. Mean perimetric deficit improved in group1 by 2.2, and by 5 in group2, whereas a decrease of over 10 dbl in group3. CMT and leackage in FA improved significantly in both treatment groups in comparison to the control. No adverse events were noticed.
Clinical Trial: :
This PDF is available to Subscribers Only